Actoplus Met is an oral medication used to treat type 2 diabetes, owned by Takeda Pharms Usa. The drug, which first hit the market on 29 August, 2005, combines the active ingredients Metformin Hydrochloride and Pioglitazone Hydrochloride. Actoplus Met is available in tablet form.
The generic version of Actoplus Met is expected to be available after 03 February, 2029, following the expiration of its last patent; US9320714 titled 'Tablet'. The release of Actoplus Met generic is contingent on the conclusion of this patent protection period.
Actoplus Met, containing Metformin Hydrochloride and Pioglitazone Hydrochloride, is utilized for the treatment of type 2 diabetes. Metformin Hydrochloride works by decreasing glucose production in the liver and absorption in the intestines while improving sensitivity to insulin. On the other hand, Pioglitazone Hydrochloride works by increasing the body's sensitivity to insulin, a natural substance that helps control blood sugar levels.
Actoplus Met holds two patents. The first, US9101660, titled 'Solid preparation', will expire on 22 January, 2027. The second, US9320714, titled 'Tablet', which dictates the generic release date, will expire on 03 February, 2029. The availability of Actoplus Met generic is dependent on these patents. Below are the details of the patents: